U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity
WASHINGTON (Reuters) - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Eating Disorders & Weight Management | Food and Drug Administration (FDA) | Health | Obesity | Victoza